|
| |
BioPortfolio's Approved Drugs DatabaseXelodaCapecitabineDownload PDF containing detailed information.
Press Releases About Xeloda:
|
 |
| Driven by the Launch of Targeted Agents, the Gastric Cancer Drug Market Will More Than Double to Nearly $1.5 Billion in 2018 |
4th November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the gastric cancer drug
|
| AEterna Zentaris Partner, Keryx, Presented Updated Phase 2 Data on Perifosine (KRX-0401) for the Treatment of Advanced Metastatic Renal Cell Carcinoma at 8th International Kidney Cancer Symposium in Chicago |
29th September, 2009 |
AETERNA ZENTARIS INC. |
Perifosine Continues to Demonstrate Impressive Efficacy, Safety and
Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed
after Failing Treatment with both a VEGF
|
| Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report |
24th September, 2009 |
Reportlinker |
-- SERMS
The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type
|
| Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer |
23rd September, 2009 |
|
BERLIN, September 23 /PRNewswire/ -- Data from the ABCSG-24 study presented today at the joint 15th ECCO and
34th ESMO congress in Berlin, Germany, show that adding capecitabine
(Xeloda(R)) to
|
| Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
1st June, 2009 |
Keryx Biopharmaceuticals, Inc. |
KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic
|
This page has been viewed 52 times
Recent Search Terms used to find this page: .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Xeloda across BioPortfolio, or for Xeloda Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
